2020 - 2021

Categories:History
Author:
Origin:
Time of issue:2021-03-09
Views:0

(Summary description)<h3 style="font-size:20px; font-weight:bold;">Milestones
</h3>
◆ Submitting the application for approval of the first generic drug for rare diseases.
◆ The new hypoglycemic drugentering Phase III clinical trials with exemption from Phase II clinical trials.
◆ Jiangsu CGenePharmaceuticalCo Ltd was established.

2020 - 2021

(Summary description)<h3 style="font-size:20px; font-weight:bold;">Milestones
</h3>
◆ Submitting the application for approval of the first generic drug for rare diseases.
◆ The new hypoglycemic drugentering Phase III clinical trials with exemption from Phase II clinical trials.
◆ Jiangsu CGenePharmaceuticalCo Ltd was established.

Categories:History
Author:
Origin:
Time of issue:2021-03-09
Views:0

Fruitful presentation

Previous: 2021 - 2022

Next: 2019 - 2020

Previous: 2021 - 2022

Next: 2019 - 2020

New Information | Series C financing of over 100 million yuan marks the first round of financing for Shengshi Taike, paving the way for commercialization of core innovative products

2024-09-04

Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, has been selected as a "Double Innovation Talent" in Jiangsu Province

Recently, the "Double Innovation Talent Plan" organized by the Jiangsu Provincial People's Government and the Provincial Talent Office was awarded a certificate of selection, and Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, was selected for the "2023 Jiangsu Province High level Innovation and Entrepreneurship Talent Introduction Plan". The Shengshi Taike R&D team led by Dr. Wang Tong is committed to the development of high-quality and differentiated small molecule innovative drugs, aiming to address major clinical pain points in the fields of blood sugar reduction, anti-tumor, and autoimmune diseases.

2024-07-31